Higher-Dose Rifampin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Sep 1, 2013 → Apr 1, 2016
NCT ID
NCT01408914About Higher-Dose Rifampin
Higher-Dose Rifampin is a phase 2 stage product being developed by Sanofi for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01408914. Target conditions include Tuberculosis.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01408914 | Phase 2 | Completed |
Competing Products
20 competing products in Tuberculosis